Hep A News

1 in 100 people 'insensitive to HIV, malaria, leprosy and hepatitis'
TruthDive
London, Feb 7 (ANI): One per cent of the population have a natural genetic resistance to deadly disease such as HIV, malaria, leprosy and hepatitis, scientists have revealed, scientists have revealed. The findings came after research into anthrax found ...

As death nears, hepatitis C victim to give videotaped deposition in Desai case
Las Vegas Review-Journal
Rodolfo Meana, pictured here in 2008, is one of seven patients diagnosed with hepatitis C that has been genetically linked to the Endoscopy Center of Southern Nevada. Meana's doctors have told him he is terminally ill. » Buy this photo Dr. Dipak Desai ...

and more »

Daily Mail
One in 100 people 'can naturally resist HIV, malaria, leprosy and hepatitis'
Daily Mail
They said this could have implications for other pathogens like HIV One per cent of the population have a natural genetic resistance to deadly disease such as HIV, malaria, leprosy and hepatitis, scientists have revealed.
1 in 100 people 'insensitive to HIV, malaria, leprosy and hepatitis'TruthDive
New study finds individual differences in anthrax susceptibilityMedical Xpress

all 14 news articles »

Culture: Impact of war on language (155)
Egyptian Gazette
In several studies of Veteran's Affairs (VA) Medical Centre patients, we find that 8-9% are positive for hepatitis C antibodies. Some VA Medical Centres had 10-20% of patients with hepatitis C antibodies. According to Dr Bradford Waters, Professor of ...

BioLineRx shares soar (again) on hep C pact; Anacor shares slide after GSK ...
FierceBiotech
Article | Follow @FierceBiotech @JohnCFierce: So does BioLineRx see itself as a hep C co. now that it has in-licensed a 2nd program, or is this about share price? Release | Follow @JohnCFierce @FierceMedDev: DNA-sequencing penetrates Norway's ...

and more »

BioLineRX soars on second hepatitis C deal
MarketWatch
By Val Brickates Kennedy BOSTON (MarketWatch) -- Shares of BioLineRx soared 33% to $5.49 on Monday on news that the Israeli drug developer has licensed an experimental treatment for hepatitis C, dubbed BL-8030, from Genoscience and RFS Pharma.

Stocks to Watch: Micron Technology, Hasbro, Alpha Natural Resources and More
Wall Street Journal (blog)
BioLineRx licensed another Hepatitis C treatment from French biotechnology company Genoscience, as the Israeli-based biopharmaceutical company expands into the field of Hepatitis C therapeutics. Shares jumped 13% to $4.65 in recent premarket trading.

and more »

Gilead Sciences Jumps on Hepatitis C Data
Pharmaceutical Processing
NEW YORK (AP) — Shares of Gilead Sciences Inc. jumped Friday after the company reported further progress of GS-7977, a newly-acquired hepatitis C treatment still in clinical testing. THE SPARK: Gilead said Thursday that in a clinical trial, ...
Does Anavex Life Sciences (AVXL) Have the Next Big Thing Big Pharma Wants?SmallCap Network
Positive Clinical Trial Results Boost Gilead the Most in Three Years – NASDAQ:GILDGalaxy Stocks
Watson Provides Update on Generic Lidoderm® Application; Gilead Soars On ...Proactive Investors USA & Canada
San Francisco Business Times (blog) -Seeking Alpha -CNBC.com
all 12 news articles »

BioLineRx Licenses Another Hepatitis C Drug From Genoscience
Wall Street Journal
BioLineRx Ltd. (BLRX) licensed another Hepatitis C treatment from French biotechnology company Genoscience, as the Israeli-based biopharmaceutical company expands into the field of Hepatitis C therapeutics. Hepatitis C is a blood-borne infection of the ...
BioLineRx In-Licenses Second Oral Hepatitis C TreatmentMarketWatch (press release)
BiolineRX signs second hepatitis C licensing dealGlobes
BioLineRx Inks License Agreement With Genoscience, RFS Pharma To Develop BL-8030RTT News

all 24 news articles »

CDC Now Recommends Hepatitis B Vaccine for Diabetics
Diets In Review (blog)
Recently the Centers for Disease Control released new recommendations for 2012 that include Hepatitis B vaccine recommended for diabetics. Diabetics have a lot on their plate, figuratively speaking of course. Not only is it their responsibility to ...

and more »

BioLineRx Inks License Agreement With Genoscience, RFS Pharma To Develop BL-8030
NASDAQ
(RTTNews.com) - BioLineRx (BLRX) announced that it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C. The agreement includes upfront ...
BioLineRx In-Licenses Second Oral Hepatitis C TreatmentMarketWatch (press release)

all 9 news articles »

BioLineRx In-Licenses Second Oral Hepatitis C Treatment
MarketWatch (press release)
The NS3 protease is essential for the replication of the Hepatitis C virus (HCV) and is an important target for HCV therapies. BL-8030 has been shown to have excellent antiviral activity against various HCV genotypes. Pre-clinical studies have ...

and more »

Inovio Pharmaceuticals to Present at BIO CEO & Investor Conference
Bradenton Herald
Inovio's clinical programs include Phase II studies for cervical dysplasia, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer ...
SciClone Pharmaceuticals to Present at BIO CEO & Investor ConferenceMarketWatch (press release)

all 18 news articles »

FDA removes hold on Idenix hepatitis drug
Pharmaceutical Business Review
IDX184 is a pan-genotypic oral nucleotide polymerase inhibitor, used for the treatment of hepatitis C virus (HCV) infection. In September 2010, FDA has issued a clinical hold as a result of three cases of elevated liver function tests observed during a ...
US FDA removes partial clinical hold on IDX184 of Idenix, allows enrollment of ...pharmabiz.com

all 2 news articles »

Taco Bell Should Learn From A Long History of Food Outbreaks
Food Poison Journal
Taco Bell Restaurants Green Onion 2000 - 30 Ill - In December, South Carolina health department workers began receiving reports of hepatitis A that were associated with eating a meal at a Taco Bell in Fruitland Park, Florida.

and more »

Local VA focuses on safer care after 2011 scandal
Dayton Daily News
While an internal VA investigation has not identified a link between the three positive cases and the care they received at the dental clinic, a team with the CDC's viral hepatitis branch for several months has been conducting a more in-depth analysis, ...
Ohio VA still probing dental clinic scandalDrBicuspid.com
VA: Hospital has "clean slate"WDTN

all 33 news articles »

US Vaccination Coverage Remained Low in 2010
Medscape
The current report covers pneumococcal, hepatitis A and B, herpes zoster (shingles), human papillomavirus (HPV), and tetanus, diphtheria, and acellular pertussis (Tdap) vaccines. A previous report covered influenza vaccinations.

MD News
Hepatitis Research May Benefit From Stem Cells
Medical News Today
Hepatitis C is a viral disease that leads to inflammation and organ failure. However, researchers are puzzled as to why some individuals are very susceptible to the disease, while others are not. Researchers believe they could find out how genetic ...
Personalized Liver Cells Support Hepatitis C VirusDoctors Lounge
Scientists establish HCV infection in liver-like cells derived from iPSCsNews-Medical.net

all 5 news articles »

March trial for Desai may be postponed again
Las Vegas Review - Journal
Buy this photo By Jeff German Dr. Dipak Desai may have been found competent to face criminal charges in the hepatitis C outbreak, but his upcoming March 12 trial is expected to be delayed again. Lawyers on both sides of the massive criminal case do not ...
FOX5 Vegas - KVVUDipak Desai found mentally fit to stand trialKVVU Las Vegas
Ex-doc ruled fit for trial in Vegas hepatitis-C caseMyNews3

all 5 news articles »

RTT News
Gilead Rises on Hepatitis C Trial Results: San Francisco Mover
BusinessWeek
3 (Bloomberg) -- Gilead Sciences Inc., the drugmaker that acquired Pharmasset Inc. last month for its experimental hepatitis C treatments, gained the most in three years after one of the medicines produced positive clinical trial results.
An all-oral hepatitis C drug may be one step closer to realityLagonian.com
Gilead Woes With New Hep C Data, Boxing Out Poor 2012 GuidanceTheStreet.com
Gilead shares surge as hep C drug scores a cure for big patient populationFierceBiotech
Wall St. Cheat Sheet -Motley Fool
all 63 news articles »